<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: It is hypothesized that BRAF mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> represent a discrete subset of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) defined by poorer survival </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigates whether BRAF mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is further defined by a distinct pattern of metastatic spread and explores the impact of BRAF mutation and microsatellite instability (MSI) on prognosis in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: By using prospective clinical data and molecular analyses from 2 major centers (Royal Melbourne Hospital and The University of Texas MD Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center), patients with known BRAF mutation status were analyzed for clinical characteristics, survival, and metastatic sites </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The authors identified 524 metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients where BRAF mutation status was known; 57 (11%) were BRAF mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>BRAF mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were significantly associated with right-sided <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, MSI, and poorer survival (median, 10.4 months vs 34.7 months, P &lt; .001) </plain></SENT>
<SENT sid="5" pm="."><plain>A distinct pattern of metastatic spread was observed in BRAF mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, namely higher rates of <z:e sem="disease" ids="C0346989" disease_type="Neoplastic Process" abbrv="">peritoneal metastases</z:e> (46% vs 24%, P = .001), distant <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> (53% vs 38%, P = .008), and lower rates of <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> (35% vs 49%, P = .049) </plain></SENT>
<SENT sid="6" pm="."><plain>In additional survival analyses, MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had significantly poorer survival compared with microsatellite stable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (22.1 months vs 11.1 months, P = .017), but this difference was not evident in the BRAF mutant population </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The pattern of metastatic spread observed in this study further defines BRAF mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> as a discrete disease subset </plain></SENT>
<SENT sid="8" pm="."><plain>The authors demonstrated that, unlikely early stage disease, MSI is associated with poorer survival in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, although this is driven by its association with BRAF mutation </plain></SENT>
</text></document>